semaglutide patent expiration 2031 to increase accessibility 2026-2031 | THE 5-YEAR PLAN

He is supported by funding from the US Department of Defense (NF210010), the National Cancer Institute of the NIH (R01 CA166593), and the Developmental and Hyperactive RAS Tumor SPORE (U54 CA196519)

This review reconsiders the debated concept of food addiction in light of these pharmacological advances, drawing on neurobiological, societal, and emerging clinical perspectives

Oxidative stressinduced calreticulin expression and translocation: new insights into the destruction of melanocytes

This reframes the conversation entirely: GLP-1 medications are best understood not as a temporary course but as treatment for obesity as a chronic, relapsing disease much as one does not stop an antihypertensive once blood pressure normalizes

The presence of H

CrossRef Diabetes mellitus and comorbidities: A bad romance Niki Katsiki, Dimitrios Tousoulis Hellenic Journal of Cardiology.2020